Navigation Links
Alexza Reports 2011 Third Quarter Financial Results and Provides Business Update
Date:11/7/2011

f $9.3 million and $34.0 million in the same periods in 2010.  Research and development expenses were $8.1 million and $21.0 million in the three and nine-month periods ended September 30, 2011, respectively, compared to $6.7 million and $22.5 million in the same periods in 2010.  General and administrative expenses were $3.1 million and $8.7 million in the three and nine-month periods ended September 30, 2011, respectively, compared to $2.6 million and $11.5 million for the same periods in 2010.

In connection with the acquisition of Symphony Allegro, Inc. in August 2009, Alexza is obligated to pay the former Symphony Allegro stockholders certain percentages of cash payments that may be generated from collaboration transactions for ADASUVE, AZ-002 (Staccato alprazolam) or AZ-104 (Staccato loxapine, low-dose).  The Company records this obligation as a contingent liability and updates the liability each quarter.  As a result of the update of the liability, Alexza recorded a non-operating loss of $3.0 million and $3.3 million during the three and nine months ended September 30, 2011 compared to a non-operating gain of $8.5 million and $7.3 million in the three and nine months ended September 30, 2010, respectively.  Gains and losses incurred reflect Alexza's change in the estimated probability-weighted cash flows from ADASUVE and the estimated timing of receipt of such cash flows.

Conference Call Information

To access the conference call via the Internet, go to www.alexza.com, under the "Investor Relations" tab.  Please join the call at least 15 minutes prior to the start of the call to ensure time for any software downloads that may be required.  Interested parties may also pre-register to avoid pre-call delays at https://www.theconferencingservice.com/prereg/key.process?key=PVXTM
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Alexza Pharmaceuticals to Present at the Lazard Capital Markets 8th Annual Healthcare Conference
2. Alexza to Announce 2011 Third Quarter Financial Results on Monday, November 7, 2011
3. Alexza Announces the Adasuve™ (Staccato® Loxapine) PDAC Meeting Date of December 12, 2011
4. Alexza Pharmaceuticals to Present at the 18th Annual NewsMakers in the Biotech Industry Conference
5. Alexza and Grupo Ferrer Establish Partnership for the Commercialization of Adasuve™ (Staccato® Loxapine) in Europe and Latin America
6. Alexza Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference
7. Alexza Announces Adasuve™ (Staccato® Loxapine) PDUFA Goal Date of February 4, 2012
8. Alexza Announces Resubmission of AZ-004 (Staccato® Loxapine) NDA
9. Alexza to Announce 2011 Second Quarter Financial Results on Monday, August 8, 2011
10. Alexza Reports 2011 First Quarter Financial Results and Provides Business Update
11. Alexza to Present at the MDB Bright Lights Conference 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... 2015  Uroplasty, Inc. (NASDAQ: UPI ), a ... proprietary products to treat voiding dysfunctions, today announced that ... on Tuesday, March 10, 2015. Rob Kill , ... Financial Officer, will present at 4:00 p.m. Pacific Time ... conference at the Ritz Carlton in Laguna ...
(Date:2/26/2015)... 2015 RnRMarketResearch.com adds Corneal ... report to its store. This report p provides ... The report "Corneal Ulcers - Pipeline Review, H2 ... for Corneal Ulcers. Corneal Ulcers are primarily result ... viral infections & fungal infections. The symptoms of ...
(Date:2/26/2015)... , Feb. 26, 2015  Mobility Ventures LLC, ... agreement with Bank of America (NYSE: BAC ... to receive financing of the revolutionary MV-1 - - ... from the ground up to provide safe and comfortable ... can use their loan to purchase a new MV-1 ...
Breaking Medicine Technology:Uroplasty to Participate in the 27th Annual ROTH Conference 2Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 2Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 3Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 4Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 5Mobility Ventures and Bank of America Announce New Agreement to Simplify Retail Consumer Financing for MV-1 Universally Accessible Vehicle 2Mobility Ventures and Bank of America Announce New Agreement to Simplify Retail Consumer Financing for MV-1 Universally Accessible Vehicle 3
... 2011 Inovio Pharmaceuticals, Inc. (NYSE Amex: ... and preventive vaccines against cancers and infectious diseases, announced ... partnering and scientific conferences: BioPartnering North ... corporate overview on Inovio at the 9th Annual BioPartnering ...
... Feb. 21, 2011 Acuo Technologies®, a market ... medical imaging industry for archiving, collaboration and migration ... Fiscal Year 2010. The company achieved 25% growth ... three-year compounded annual growth rate of 55% in ...
Cached Medicine Technology:Inovio Pharmaceuticals to Present at Partnering and Scientific Conferences 2Inovio Pharmaceuticals to Present at Partnering and Scientific Conferences 3Acuo Technologies Announces Another Significant Growth Year in Revenue and Implementations to Further the Company's Market Leading Position 2
(Date:2/28/2015)... Heart diseases are on the rise ... urban adult population and 5 percent of rural adult ... 20-30 percent of them require specialized investigation and treatment ... vascular diseases (CVD). , A division of Indian Business ... report titled “Indian Coronary Stent Market Forecast to 2019”. ...
(Date:2/28/2015)... Gerald “Solutionman” Haman surveyed over 10,000 ... to innovative thinking. “The #1 block was lack ... tools,” reports Haman, who created the Thinkubator Innovation Studio ... felt that they did not have enough time for ... to stimulate innovation. , Solutionman’s monthly “Accelerating Innovation Training” ...
(Date:2/28/2015)... February 28, 2015 The Heart Fit ... a distributor of the machine. The Heart Fit Clinic ... license, like a franchise model. The goal is to ... reverse heart disease. To buy External Counterpulsation ... can help individuals through this process and achieve the ...
(Date:2/28/2015)... March—also known as National Brain Injury ... and others that suspected head injuries, especially concussions, ... , Concussions are a form of traumatic brain ... There are 1.6-3.8 million sports-related concussions per year. ... is a brain injury. Many athletes suffer knee ...
(Date:2/28/2015)... Vancouver personal injury lawyers at Jiwa Law Corporation recently announced ... They stated that in many cases, missing an important time ... Many a time, delays in making an injury claim can ... As a result, experts at Jiwa Law Corporation suggest that ... injury lawyer in order to know more about their rights. ...
Breaking Medicine News(10 mins):Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 2Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 3Health News:New Survey Reveals “Lack of Time” Is the Number #1 Barrier to Innovative Thinking 2Health News:New Survey Reveals “Lack of Time” Is the Number #1 Barrier to Innovative Thinking 3Health News:Clinicians Can Now Purchase External Counterpulsation with Heart Fit Clinic 2Health News:Atlantic NeuroSurgical Specialists (ANS) Focus on National Brain Injury Awareness Month to Educate the General Public on Head Trauma 2Health News:Atlantic NeuroSurgical Specialists (ANS) Focus on National Brain Injury Awareness Month to Educate the General Public on Head Trauma 3Health News:Jiwa Law Corporation Recently Announced That Time Delays May Weaken Personal Injury Claims 2
... Iceland, Oct. 15 deCODE genetics,(Nasdaq: DCGN ... out a review of,its long-term business strategy. Over ... in medicinal chemistry, structural biology and,human genetics to ... and DNA-based diagnostics. The goal of this strategic,review ...
... Lot Number 77946, 81141 and 81142 NDC #58177-311-04, ... it has voluntarily recalled three specific lots (77946, 81141 ... precaution, due to,the possible presence of oversized tablets. Oversized ... amount of the active ingredient. The,recalled lots were distributed ...
... home after a drink with a friend on 28 August 2005 ... thrown through the windscreen, suffered massive head injuries and fell into ... of improvement. "He would open his eyes, but he was not ... of the US Department of Veterans Affairs in Chicago, who helped ...
... Oct. 15 CTG HealthCare Solutions,(CTGHS), a leading ... unit of CTG (Nasdaq: CTGX ), an ... it was awarded a series of,engagements in support ... providing services to a major children,s hospital with ...
... Saturday, November 1, 2008 - 4:00-5:00 pm, ... Ca.), SAN FRANCISCO, Oct. 14 AASLD President ... the first full day of,presentations at the Liver Meeting(R), ... of Liver Diseases., Dr. McCullough will highlight individual ...
... Warner Chilcott,Limited (Nasdaq: WCRX ) announced today that ... to the market opening on Monday, November 10,2008., ... will host a,conference call for all interested parties on ... review the results. To participate in the call,please dial ...
Cached Medicine News:Health News:deCODE Conducting Strategic Review to Sharpen the Focus of its Long-term Business 2Health News:deCODE Conducting Strategic Review to Sharpen the Focus of its Long-term Business 3Health News:deCODE Conducting Strategic Review to Sharpen the Focus of its Long-term Business 4Health News:ETHEX Corporation Voluntarily Recalls Three Lots of Dextroamphetamine Sulfate 5mg Tablets Due to the Potential for Oversized Tablets 2Health News:ETHEX Corporation Voluntarily Recalls Three Lots of Dextroamphetamine Sulfate 5mg Tablets Due to the Potential for Oversized Tablets 3Health News:ETHEX Corporation Voluntarily Recalls Three Lots of Dextroamphetamine Sulfate 5mg Tablets Due to the Potential for Oversized Tablets 4Health News:Patient roused from coma by a magnetic field 2Health News:Patient roused from coma by a magnetic field 3Health News:CTG HealthCare Solutions Announces New EPIC Implementation Engagements 2Health News:CTG HealthCare Solutions Announces New EPIC Implementation Engagements 3Health News:American Association for the Study of Liver Diseases (AASLD) President's Press Conference, Nov. 1, 2008 in San Francisco 2
ThyroTest TSH is a rapid, qualitative test for hypothyroidism screening in adults....
... is an ultra-high speed, high resolution optical ... retina imaging and analysis. It ... Optical Coherence technology just emerging from clinical ... The ultra-high speed and high resolution ...
... finest surgical-quality loupes available at ... for innovative optical design, combining superior ... optimum performance with maximum comfort, SheerVision ... medical professionals worldwide. All SheerVision loupes ...
... the finest surgical-quality loupes available ... standard for innovative optical design, combining ... Delivering optimum performance with maximum comfort, ... for medical professionals worldwide. All SheerVision ...
Medicine Products: